


Ask a doctor about a prescription for Nomigren
migraine.
Almotriptan
This medicine should always be used exactly as described in this patient leaflet or as directed by a doctor or pharmacist.
is a migraine medicine that belongs to a group of medicines called selective serotonin receptor agonists. The active substance - almotriptan binds to serotonin receptors in blood vessels in the brain (skull) causing them to constrict, which leads to a reduction in the inflammatory response associated with migraine.
The medicine is used for the acute treatment of headache in acute migraine attacks with or without aura.
The medicine can only be used in patients who have been diagnosed with migraine by a doctor.
The medicine should not be used for migraine prevention.
In case of doubt, consult a doctor or pharmacist.
Migraine is characterized by moderate or severe headache. The pain affects one side of the head, is pulsating, and worsens with physical activity. The pain is accompanied by at least one of the following symptoms: nausea, vomiting, sensitivity to light, sounds, or smells.
Headache can sometimes be preceded by certain symptoms, such as short-term mood deterioration, irritation, anxiety, or loss of appetite. In some people, shortly before the onset of headache, a so-called aura may appear (transient visual disturbances with a sensation of light flashes, flickering spots, or lines of light).
Before starting to use the medicine, discuss it with a doctor or pharmacist:
It is believed that excessive use of migraine medicines may lead to chronic headache.
The medicine contains less than 1 mmol (23 mg) of sodium per tablet, which means the medicine is considered "sodium-free".
The medicine should not be used in children and adolescents under 18 years of age.
If the patient is over 65 years old, they should not use this medicine without consulting a doctor.
Tell your doctor or pharmacist about all medicines you are taking now or have taken recently, as well as any medicines you plan to take.
Tell your doctor:
Do not take almotriptan at the same time as medicines containing ergotamine, which may also be used to treat migraine. However, you can take these medicines one after the other, provided you leave a suitable time interval between their administration:
The medicine can be taken with or without food. The medicine should be taken with a liquid (e.g., water).
If you are pregnant or breastfeeding, think you may be pregnant, or plan to have a child, consult your doctor or pharmacist before taking this medicine.
There are only limited data on the use of almotriptan in pregnant women.
The medicine should not be used during pregnancy, unless advised by a doctor who has carefully weighed the benefits and risks.
Caution should be exercised when using this medicine during breastfeeding. You should avoid breastfeeding for 24 hours after taking this medicine.
may cause drowsiness. While taking this medicine, do not drive or operate any tools or machines.
This medicine should always be used exactly as described in the patient leaflet or as directed by a doctor or pharmacist. In case of doubt, consult a doctor or pharmacist.
should only be used for the treatment of an ongoing migraine attack and not for the prevention of migraine attacks or headaches.
The medicine can only be used in patients with diagnosed migraine.
The medicine should not be used for migraine prevention.
The recommended dose is one tablet (12.5 mg). The tablet should be taken as soon as possible after the onset of a migraine attack. If the migraine attack does not subside, do not take more than one tablet during the same attack.
If the patient experiences another migraine attack within 24 hours, a second tablet can be taken at a dose of 12.5 mg, provided that at least a 2-hour interval is maintained between the administration of the first and second tablets.
The maximum daily dose is two tablets (25 mg) within 24 hours.
The tablet should be swallowed with a liquid (e.g., water). The tablet can be taken with or without food.
The medicine should be taken as soon as possible after the onset of a migraine attack, but it is also effective when taken at a later stage.
Severe kidney disease
If the patient has severe kidney disease, do not take more than one 12.5 mg tablet in 24 hours.
If you have taken too many tablets or if someone else or a child has taken the medicine, consult a doctor or pharmacist immediately.
Do not take a double dose to make up for a missed dose.
If you have any further doubts about the use of this medicine, consult a doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
During treatment with the medicine, immediately consult a doctor and do not take any more tablets of the medicine if you experience the following symptoms:
Other side effects:
Common side effects(may affect up to 1 in 10 people):
Uncommon side effects(may affect up to 1 in 100 people):
Rare side effects(may affect up to 1 in 10,000 people):
Frequency not known(frequency cannot be estimated from the available data):
If you experience any side effects, including any side effects not listed in this leaflet, tell your doctor or pharmacist. Side effects can be reported directly to the Department of Adverse Reaction Monitoring of Medicinal Products, Medical Devices, and Biocides of the Office for Registration of Medicinal Products:
Aleje Jerozolimskie 181C, 02-222 Warsaw
tel.: +48 22 49 21 301, fax: +48 22 49 21 309
Website: https://smz.ezdrowie.gov.pl
Side effects can also be reported to the marketing authorization holder.
Reporting side effects will help to gather more information on the safety of the medicine.
Keep the medicine out of sight and reach of children.
Do not use this medicine after the expiry date stated on the packaging. The expiry date refers to the last day of the month.
There are no special precautions for storing the medicine.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.
The medicine is a white, round, biconvex, film-coated tablet.
One pack of the medicine contains 2 or 6 film-coated tablets in OPA/Aluminum/PVC/Aluminum blisters, in a cardboard box.
PHARMACEUTICAL COMPANY HASCO-LEK S.A.
51-131 Wroclaw, ul. Żmigrodzka 242 E
tel.: +48 71 352 95 22
fax: +48 71 352 76 36
Chanelle Medical Unlimited Company
Dublin Road, H62 FH90 Loughrea
Ireland
tel.: (22) 742 00 22
e-mail: [email protected]
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for Nomigren – subject to medical assessment and local rules.